메뉴 건너뛰기




Volumn 22, Issue 4, 2017, Pages 315-324

Pharmacogenetic testing for the guidance of psychiatric treatment: A multicenter retrospective analysis

Author keywords

anxiety; bipolar disorder; depression; genomics; personalized medicine; pharmacogenetics; psychiatric treatment; psychotic disorder

Indexed keywords

ADULT; ADVERSE OUTCOME; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL OUTCOME; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC ANALYSIS; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NATURALISTIC INQUIRY; OBSERVATIONAL STUDY; PHARMACOGENETIC TESTING; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SPAIN; ANXIETY DISORDERS; BIPOLAR DISORDER; CLINICAL TRIAL; DEPRESSIVE DISORDER; MENTAL DISORDERS; MIDDLE AGED; MULTICENTER STUDY; ODDS RATIO; PERSONALIZED MEDICINE; PSYCHOTIC DISORDERS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84973878606     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852915000711     Document Type: Article
Times cited : (34)

References (24)
  • 1
    • 84871051576 scopus 로고    scopus 로고
    • Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010
    • Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859): 2163-2196.
    • (2012) Lancet , vol.380 , Issue.9859 , pp. 2163-2196
    • Vos, T.1    Flaxman, A.D.2    Naghavi, M.3
  • 2
    • 79952449206 scopus 로고    scopus 로고
    • Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication
    • McClintock SM, Husain MM, Wisniewski SR, et al. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol. 2011; 31(2): 180-186.
    • (2011) J Clin Psychopharmacol , vol.31 , Issue.2 , pp. 180-186
    • McClintock, S.M.1    Husain, M.M.2    Wisniewski, S.R.3
  • 3
    • 33751338530 scopus 로고    scopus 로고
    • Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR,D report
    • Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR,D report. Am J Psychiatry.2006; 163(11): 1905-1917.
    • (2006) Am J Psychiatry , vol.163 , Issue.11 , pp. 1905-1917
    • Rush, A.J.1    Trivedi, M.H.2    Wisniewski, S.R.3
  • 5
    • 33745399074 scopus 로고    scopus 로고
    • Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression
    • Dunner DL, Rush AJ, Russell JM, et al. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry. 2006; 67(5): 688-695.
    • (2006) J Clin Psychiatry , vol.67 , Issue.5 , pp. 688-695
    • Dunner, D.L.1    Rush, A.J.2    Russell, J.M.3
  • 6
    • 84872663272 scopus 로고    scopus 로고
    • Evidence-based treatment strategies for treatment-resistant bipolar depression: A systematic review
    • Sienaert P, Lambrichts L, Dols A, De Fruyt J. Evidence-based treatment strategies for treatment-resistant bipolar depression: A systematic review. Bipolar Disord. 2013; 15(1): 61-69.
    • (2013) Bipolar Disord. , vol.15 , Issue.1 , pp. 61-69
    • Sienaert, P.1    Lambrichts, L.2    Dols, A.3    De Fruyt, J.4
  • 7
    • 77955302215 scopus 로고    scopus 로고
    • The pharmacologic treatment of anxiety disorders: A review of progress
    • Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders: A review of progress. J Clin Psychiatry. 2010; 71(7): 839-854.
    • (2010) J Clin Psychiatry , vol.71 , Issue.7 , pp. 839-854
    • Ravindran, L.N.1    Stein, M.B.2
  • 8
    • 25144456112 scopus 로고    scopus 로고
    • Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
    • Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12): 1209-1223.
    • (2005) N Engl J Med , vol.353 , Issue.12 , pp. 1209-1223
    • Lieberman, J.A.1    Stroup, T.S.2    McEvoy, J.P.3
  • 9
    • 84907278618 scopus 로고    scopus 로고
    • Treatment resistant schizophrenia: A comprehensive survey of randomised controlled trials
    • Sinclair D, Adams CE. Treatment resistant schizophrenia: A comprehensive survey of randomised controlled trials. BMC Psychatry. 2014; 14: 253.
    • (2014) BMC Psychatry , vol.14 , pp. 253
    • Sinclair, D.1    Adams, C.E.2
  • 10
    • 40549089935 scopus 로고    scopus 로고
    • Influence of the CYP2D6,4 polymorphism on dose, switching and discontinuation of antidepressants
    • Bijl MJ, Visser LE, Hofman A, et al. Influence of the CYP2D6,4 polymorphism on dose, switching and discontinuation of antidepressants. Br J Clin Pharmacol. 2008; 65(4): 558-564.
    • (2008) Br J Clin Pharmacol , vol.65 , Issue.4 , pp. 558-564
    • Bijl, M.J.1    Visser, L.E.2    Hofman, A.3
  • 11
    • 77951844279 scopus 로고    scopus 로고
    • Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder
    • Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry. 2010; 15(5): 473-500.
    • (2010) Mol Psychiatry , vol.15 , Issue.5 , pp. 473-500
    • Kato, M.1    Serretti, A.2
  • 12
    • 84856209453 scopus 로고    scopus 로고
    • Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: A replication study
    • Risselada AJ, Vehof J, Bruggeman R, et al. Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: A replication study. Pharmacogenomics J. 2012; 12(1): 62-67.
    • (2012) Pharmacogenomics J , vol.12 , Issue.1 , pp. 62-67
    • Risselada, A.J.1    Vehof, J.2    Bruggeman, R.3
  • 13
    • 84898047653 scopus 로고    scopus 로고
    • Pharmacogenomic testing for neuropsychiatric drugs: Current status of drug labeling, guidelines for using genetic information, and test options
    • Drozda K, Müller DJ, Bishop J.R. Pharmacogenomic testing for neuropsychiatric drugs: Current status of drug labeling, guidelines for using genetic information, and test options. Pharmacotherapy. 2014; 34(2): 166-184.
    • (2014) Pharmacotherapy , vol.34 , Issue.2 , pp. 166-184
    • Drozda, K.1    Müller, D.J.2    Bishop, J.R.3
  • 14
    • 84876665512 scopus 로고    scopus 로고
    • Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants
    • Hicks JK, Swen JJ, Thorn CF, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther.2013; 93(5): 402-408.
    • (2013) Clin Pharmacol Ther , vol.93 , Issue.5 , pp. 402-408
    • Hicks, J.K.1    Swen, J.J.2    Thorn, C.F.3
  • 15
    • 79955463893 scopus 로고    scopus 로고
    • Pharmacogenetics: From bench to byte-an update of guidelines
    • Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: From bench to byte-an update of guidelines. Clin Pharmacol Ther.2011; 89(5): 662-673.
    • (2011) Clin Pharmacol Ther , vol.89 , Issue.5 , pp. 662-673
    • Swen, J.J.1    Nijenhuis, M.2    De Boer, A.3
  • 16
    • 38149003759 scopus 로고    scopus 로고
    • Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression
    • Uhr M, Tontsch A, Namendorf C, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron.2008; 57(2): 203-209.
    • (2008) Neuron , vol.57 , Issue.2 , pp. 203-209
    • Uhr, M.1    Tontsch, A.2    Namendorf, C.3
  • 17
    • 84931335155 scopus 로고    scopus 로고
    • Análisis Farmacogenético en psiquiatriá estudio descriptivo de una experiencia clínica con 21 pacientes
    • Vega M, Sánchez P, Garciá M, et al. Análisis Farmacogenético en psiquiatriá, estudio descriptivo de una experiencia clínica con 21 pacientes. Psiquiatria.com. 2012; 16: 5.
    • (2012) Psiquiatria.com , vol.16 , pp. 5
    • Vega, M.1    Sánchez, P.2    Garciá, M.3
  • 18
    • 84881377249 scopus 로고    scopus 로고
    • Medication nonadherence and psychiatry
    • Chapman SCE, Horne R. Medication nonadherence and psychiatry. Curr Opin Psychiatry. 2013; 26(5): 446-452.
    • (2013) Curr Opin Psychiatry , vol.26 , Issue.5 , pp. 446-452
    • Chapman, S.C.E.1    Horne, R.2
  • 19
    • 84901255199 scopus 로고    scopus 로고
    • Providing patients with pharmacogenetic test results affects adherence to statin therapy: Results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial
    • Charland SL, Agatep BC, Herrera V, et al. Providing patients with pharmacogenetic test results affects adherence to statin therapy: Results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial. Pharmacogenomics J.2014; 14(3): 272-280.
    • (2014) Pharmacogenomics J. , vol.14 , Issue.3 , pp. 272-280
    • Charland, S.L.1    Agatep, B.C.2    Herrera, V.3
  • 20
    • 84889610517 scopus 로고    scopus 로고
    • A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder
    • Winner J, Carhart JM, Altar CA, Allen JD, Dechairo BM. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discov Med. 2013; 16(89): 219-227.
    • (2013) Discov Med , vol.16 , Issue.89 , pp. 219-227
    • Winner, J.1    Carhart, J.M.2    Altar, C.A.3    Allen, J.D.4    Dechairo, B.M.5
  • 21
    • 84885082776 scopus 로고    scopus 로고
    • Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting
    • Hall-Flavin DK, Winner JG, Allen JD, et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics. 2013; 23(10): 535-548.
    • (2013) Pharmacogenet Genomics , vol.23 , Issue.10 , pp. 535-548
    • Hall-Flavin, D.K.1    Winner, J.G.2    Allen, J.D.3
  • 22
    • 84880452154 scopus 로고    scopus 로고
    • Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression
    • Winner J, Allen JD, Anthony Altar C, Spahic-Mihajlovic A. Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Transl Psychiatry. 2013; 3: E242.
    • (2013) Transl Psychiatry , vol.3 , pp. E242
    • Winner, J.1    Allen, J.D.2    Anthony Altar, C.3    Spahic-Mihajlovic, A.4
  • 23
    • 84883746349 scopus 로고    scopus 로고
    • Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs
    • Herbild L, Andersen SE, Werge T, Rasmussen HB, Jürgens G. Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costsBasic Clin Pharmacol Toxicol. 2013; 113(4): 266-272.
    • (2013) Basic Clin Pharmacol Toxicol , vol.113 , Issue.4 , pp. 266-272
    • Herbild, L.1    Andersen, S.E.2    Werge, T.3    Rasmussen, H.B.4    Jürgens, G.5
  • 24
    • 84901707207 scopus 로고    scopus 로고
    • The clinical application of ABCB1 genotyping in antidepressant treatment: A pilot study
    • Breitenstein B, Scheuer S, Pfister H, et al. The clinical application of ABCB1 genotyping in antidepressant treatment: A pilot study. CNS Spectr.2014; 19(2): 165-175.
    • (2014) CNS Spectr , vol.19 , Issue.2 , pp. 165-175
    • Breitenstein, B.1    Scheuer, S.2    Pfister, H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.